Overview

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Status:
Active, not recruiting

Trial end date:
2022-01-30

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies, Monoclonal
Pembrolizumab
Ramucirumab